|
KMID : 0360319930250040461
|
|
Journal of Korean Cancer Research Association
1993 Volume.25 No. 4 p.461 ~ p.467
|
|
|
FAM Versus Etoposide, Adriamycin, and Cisplatin: A Random Assignment Trial in Advanced Gastric Cancer
|
|
이정애
윤성수/양성현/김시영/허대석/방영주/조경삼/김노경
|
|
|
Abstract
|
|
|
Gastric cancer is the most common malignancy in Korea. Cure for patients with gastric carcinoma can be achieved only in complete surgical resection. Despite the availability of radical surgical procedures, the majority of patients with this
disease
have
poor prognosis. Therefore, the development of effective systemic therapy is essential if the outcome for patients with gastric cancer is to be improved.
Preusser at al from Germany reported their experience in treatment of 67 patients with advanced gastric adenocarcinoma with etoposide, doxorubicin, and cisplatin(EAP) combination chemotherapy. Responses were observed in 43 of 67(64%) patients in
which
14(21%) complete responses were included.
Between February 1991 and September 1992, 63 previously untreated patients with advanced gastric adenocarcinoma were randomly assigned to receive either FAM regimen(5-FU, adriamycin, and mitomycin-C) or EAP regimen(etoposide, adriamycin, and
cisplatin).
In 56 evaluable patients(27 for FAM and 29 for EAP), the response rates were 33%(FAM) and 3%(EAP). The median duration of remission were 13 weeks(FAM) and 57 weeks in one responder (EAP). The median survival times were 37 weeks(FAM) and 28
weeks(EAP).
The difference in the survival curves for two regimens was not statistically significant. Non-hematologic toxicities were more frequently observed in EAP regimen, but hematologic toxicities were mild and similar in the two groups.
These results suggest that EAP regimen is not superior to FAM regimen in the treatment of advanced gastric cancer.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|